Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment

Yashiro, Mika; Maejima, Hideki; Taniguchi, Tomonori; Katsuoka, Kensei; Kimura, Michiko; Wada, Mayuko

doi:10.1684/ejd.2013.2006

Cited by 11 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We identified 12 postmarketing cases, including 8 from the FAERS database and 4 cases from PubMed. [6][7][8][9] The 12 cases comprised 7 interstitial pneumonia (58%), 3 eosinophilic pneumonia (25%), 1 organizing pneumonia (8%), and 1 hypersensitivity pneumonitis (8%) diagnoses. Of the 12 cases, 7 (58%) were men and 5 (42%) were women, with a median (range) age of 63 (27-80) years.…”

Section: Resultsmentioning

confidence: 99%

“…Hypersensitivity reactions are not dose dependent and may occur with prior sensitization to the drug or result from cross-reactive antigens. In eosinophilic pneumonia, Yashiro et al 8 speculate that the inhibitory effect on IL-12 and IL-23 by ustekinumab may have impeded helper T cells T H 1 and T H 17 activity, to bring about a T H 2-dominant response and trigger the onset of eosinophilic pneumonia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of Noninfectious Pneumonia With Ustekinumab Use

2019

View full text Add to dashboard Cite

and Drug Administration (FDA) conducts ongoing public health safety surveillance for drug and therapeutic biologic products. Identifying cases of acute and subacute noninfectious pneumonia supports the public health mission of the FDA.OBJECTIVE To identify and analyze postmarketing cases of noninfectious pneumonia associated with ustekinumab use. DESIGN, SETTING, AND PARTICIPANTSThis retrospective analysis of postmarketing (spontaneous) case reports reviewed the FDA Adverse Event Reporting System (FAERS) and the PubMed databases from September 25, 2009, through November 20, 2017. Twelve cases of new-onset acute and subacute noninfectious pneumonia were identified after general marketing of ustekinumab. Cases were excluded if the time to symptom onset was more than 2 years from ustekinumab initiation and if an alternative origin for the noninfectious pneumonia (other than drug-induced) was reported. MAIN OUTCOMES AND MEASURESCases of noninfectious pneumonia associated with ustekinumab use were analyzed for baseline and demographic information, reason for ustekinumab use, symptoms, time to onset, dose sequence, laboratory and diagnostic information, and clinical outcome. RESULTSOf the 12 cases, 8 were identified from the FAERS database and 4 from PubMed. The 12 cases (7 men [58%] and 5 women [42%], with a median [range] age of 63 [27-80] years) included 7 interstitial pneumonia (58%), 3 eosinophilic pneumonia (25%), 1 organizing pneumonia (8%), and 1 hypersensitivity pneumonitis (8%) diagnoses. All 12 cases reported a serious outcome, including 7 hospitalizations (58%) and 1 respiratory failure requiring mechanical ventilation (8%). No outcome of death was reported. All 12 cases were supportive of a temporal association; specifically, in 9 cases (75%), the pulmonary symptoms appeared after 1 to 3 doses of ustekinumab. In addition, 7 cases (58%) of positive dechallenge were reported, including 1 case of a positive rechallenge. CONCLUSIONS AND RELEVANCEThe postmarketing cases suggest an association between noninfectious pneumonia and use of ustekinumab; these findings have led to the addition of a new warning for ustekinumab users regarding the risk of developing noninfectious pneumonia.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association of Noninfectious Pneumonia With Ustekinumab Use

2019

View full text Add to dashboard Cite

show abstract

“…Un cas de pneumopathie à éosinophiles sous ustékinumab a déjà été rapporté [6], qui nous a fait évoquer la responsabilité de ce médicament chez notre patient. Il s'agissait d'un patient de 67 ans qui avait développé une toux fébrile six semaines après l'introduction de l'ustékinumab, sans amélioration après antibiothérapie.…”

Section: Discussionunclassified

“…Une hypothèse physiopathologique serait que la diminution des interleukines 12 et 23 par l'ustékinumab inhibe la réponse TH1, entraînant une augmentation de la réponse Th2 [6]. Plusieurs médiateurs sont augmentés dans le liquide broncho-alvéolaire, dont les cytokines Th2 : IL-3, IL-5, Il13 et IL-18 [8].…”

Section: Discussionunclassified

Pneumopathie à éosinophiles chez un patient atteint de psoriasis en plaques traité par ustékinumab

Bretèque

Vecchi

Zéboulon

et al. 2015

Annales de Dermatologie et de Vénéréologie

View full text Add to dashboard Cite

“…Ikko KAJIHARA, 1 Katsunari MAKINO, 1 Asako ICHIHARA, 1 Satoshi FUKUSHIMA, 1 Masatoshi JINNIN, 1 Sayuri HIROOKA, 2 Keisuke KOJIMA, 2 Hirotsugu KOUROGI, 2 Hironobu IHN 1…”

Section: Conflict Of Interest: Nonementioning

confidence: 99%

Immunoglobulin G4‐related disease in a psoriasis vulgaris patient treated with ustekinumab

Kajihara

Makino

Ichihara

et al. 2014

The Journal of Dermatology

View full text Add to dashboard Cite

REFERENCES1 Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 2007; 20: 308-313. 2 To-o K, Nomura K, Sugimoto K, Nishimura T, Kuriki T, Itoh M. Experimental study on cross-reactivity of a-arbutin toward p-phenylenediamine and hydroquinone in guinea pigs. J Dermatol 2010; 37: 455-462. 3 Mishra SN, Dhurat RS, Deshpande DJ, Nayak CS. Diagnostic utility of dermatoscopy in hydroquinone-induced exogenous ochronosis. Int J Dermatol 2013; 52: 413-417. 4 Kligman AM, Willis I. A new formula for the depigmenting human skin. Arch Dermatol 1975; 111: 40-48. 5 Nath AK, Thappa DM. Kumkum-induced dermatitis: an analysis of 46 cases. Clin Exp Dermatol 2007; 32: 385-387.

show abstract

Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment

Cited by 11 publications

References 0 publications

Association of Noninfectious Pneumonia With Ustekinumab Use

Association of Noninfectious Pneumonia With Ustekinumab Use

Pneumopathie à éosinophiles chez un patient atteint de psoriasis en plaques traité par ustékinumab

Immunoglobulin G4‐related disease in a psoriasis vulgaris patient treated with ustekinumab

Contact Info

Product

Resources

About